Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

ProPhase Labs (PRPH) Liabilities from Discontinued Operations (2023 - 2024)

Historic Liabilities from Discontinued Operations for ProPhase Labs (PRPH) over the last 2 years, with Q4 2024 value amounting to $5.9 million.

  • ProPhase Labs' Liabilities from Discontinued Operations rose 10064.98% to $5.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.9 million, marking a year-over-year increase of 10064.98%. This contributed to the annual value of $5.9 million for FY2024, which is 10064.98% up from last year.
  • ProPhase Labs' Liabilities from Discontinued Operations amounted to $5.9 million in Q4 2024, which was up 10064.98% from $2.9 million recorded in Q4 2023.
  • ProPhase Labs' Liabilities from Discontinued Operations' 5-year high stood at $5.9 million during Q4 2024, with a 5-year trough of $2.9 million in Q4 2023.